Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
Upon closing of the transaction, Cantargia will receive a USD 33 million upfront cash payment, and Cantargia is eligible to up to an additional USD 580 million in milestone payments. Cantargia is also entitled to up to double digits tiered earn-out payments from global product sales.
The Vinge team includes Sofie Nordgren, Christian Lindhé, Martin Madsen Svanberg and Carolina Lundh.
